Do you want to read an article? Please log in or register.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Genitourinary Cancer
COMMENTED
Related content
Genitourinary Cancer
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M, PROSPER Investigators.
doi: 10.1056/NEJMoa2003892.
RECOMMENDED
Genitourinary Cancer
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators
doi: 10.1056/NEJMoa1815671.
Genitourinary Cancer
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN
doi: 10.1056/NEJMoa1800536.
COMMENTED
Genitourinary Cancer
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Prostate.
Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS
doi: 10.1002/pros.24053.
Genitourinary Cancer
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Eur Urol.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM
doi: 10.1016/j.eururo.2020.04.061.
Genitourinary Cancer
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
Eur J Cancer.
van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N
doi: 10.1016/j.ejca.2020.05.001.
Genitourinary Cancer
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Lancet Oncol.
Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.
Genitourinary Cancer
Olaparib for Metastatic Castration-Resistant Prostate Cancer
N Engl J Med.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
doi: 10.1056/NEJMoa1911440.
Genitourinary Cancer
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
Eur J Cancer
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K
doi: 10.1016/j.ejca.2021.06.010